Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20091857 | 0.80 | TYK2 (0.44) | HTTTYK2ALDH1A1KAT6AMAPT | |
| SCHEMBL20150156 | 0.80 | TYK2 (0.45) | TYK2CYP19A1POLBALDH1A1KAT6A | |
| SCHEMBL20150155 | 0.75 | HPGD (0.53) | HTTPOLBALDH1A1MAPTCYP2C9 | |
| SCHEMBL20225763 | 0.75 | TSHR (0.53) | HTTCYP19A1POLBALDH1A1MAPT | |
| SCHEMBL26124496 | 0.74 | HPGD (0.59) | HTTPOLBALDH1A1MAPTCYP2C9 | |
| SCHEMBL20150148 | 0.74 | HTT (0.57) | HTTALDH1A1MAPTHTR6 | |
| SCHEMBL27181513 | 0.72 | MAPT (0.63) | ALDH1A1MAPTCYP2C9 | |
| SCHEMBL29686179 | 0.71 | TSHR (0.50) | HTTCYP19A1POLBALDH1A1MAPT | |
| SCHEMBL3617121 | 0.71 | CYP19A1 (0.50) | HTTCYP19A1ALDH1A1 | |
| SCHEMBL29739895 | 0.71 | CYP19A1 (0.49) | HTTCYP19A1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | HTT 1087/4885TYK2 1/4885CYP19A1 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.